Abstracts tagged "Outcome measures"

Abstract Number: 0710 • ACR Convergence 2022
Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
Naomi Patel¹, Xiaosong Wang², Xiaoqing Fu³, Yumeko Kawano², Claire Cook³, Kathleen Vanni², Grace Qian², Emily Banasiak², Emily Kowalski², yuqing zhang⁴, Jeffrey Sparks⁵ and Zachary Wallace³, ¹Massachusetts General Hospital, Sale Creek, TN, ²Brigham and Women's Hospital, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Some patients with rheumatic disease on DMARDs may be at increased risk of poor response to SARS-CoV-2 vaccines and thus breakthrough COVID-19 infections. We…
Abstract Number: 1079 • ACR Convergence 2022
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Vanesa Calvo Río², Javier Loricera³, Nuria Aviles⁴, Juan M Blanco Madrigal⁵, Santos Castañeda⁶, Miguel Angel Gonzalez Gay⁷ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Valdecilla Hospital, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Perpetuo Socorro, Albacete, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Universitario Marques de Valdecilla, Lugo, Spain
Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…
Abstract Number: 1370 • ACR Convergence 2022
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Gulnara Mamyrova¹, William Nguyen², Hassan Awal¹, Derek Jones¹, Alison Ehrlich³, Kathleen Brindle⁴, Shahriar Haji-Momenian⁴, Robert Sheets⁵, Adeline Y. Chin⁶, Shajia Lu⁷, Massimo Gadina⁷, Hanna Kim⁸, Olcay Y. Jones⁹, Lisa G Rider¹⁰ and Rodolfo V Curiel¹, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, ³Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Department of Radiology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, CA, ⁶Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁷Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁰Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: This open-label 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (JDM).Methods: Ten patients of…
Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Mary Grace Whelan¹, Keigo Hayashi² and Sara Tedeschi¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…
Abstract Number: 2093 • ACR Convergence 2022
Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort
Farah Tamirou and Frédéric A. Houssiau, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: While long-term follow-up (FU) is needed to unmask poor outcome in lupus nephritis (LN), most clinical trials evaluate outcome measures at short-term. Early endpoints…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0751 • ACR Convergence 2021
Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?
Philip Mease¹, Vibeke Strand², Dan Furst³, Evan Siegel⁴, Melissa Mcilraith⁵, Elaine Husni⁶ and M. Cameron Hay⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Stanford University School of Medicine, Portola Valley, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴Arthritis and Rheumatism Associates, Potomac, MD, ⁵M.Mc. Consulting, Dallas, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷Miami University (Ohio), Oxford, OH
Background/Purpose: Psoriatic Arthritis (PsA) affects multiple attributes of patient health; to assess treatment effectiveness a compilation of Patient Reported Outcomes (PRO) have been utilized. While…
Abstract Number: 1026 • ACR Convergence 2021
Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study
Sung Kyung Cho¹, Lorinda Chung² and David Fiorentino³, ¹University of Texas Southwestern, Dallas, TX, ²Stanford University, Palo Alto, CA, ³Stanford University, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a chronic idiopathic inflammatory myopathy with variable clinical course, but little is known regarding factors associated with remission of disease. We…
Abstract Number: 1410 • ACR Convergence 2021
Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis
Kathleena D'Anna¹, David Lim², Lorena Salto¹ and Mehrnaz Hojjati¹, ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University Health, Redlands, CA
Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in North America, typically affecting Caucasian female adults over 50 years of age. Flares…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 0756 • ACR Convergence 2021
Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis
R Naveen¹, Darpan R Thakare², Vikas Agarwal², Rohit Aggarwal³ and Latika Gupta¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered…
Abstract Number: 1154 • ACR Convergence 2021
What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching
Sabina Gall, Uta Kiltz, Tanja Kobylinski, Ioana Andreica, Kristina Vaupel, Xenofon Baraliakos and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The market share of biosimilars (bsDMARDs) is steadily growing, not only in rheumatologic care. Although data on efficacy, efficiency and safety have been generated…
Abstract Number: 1451 • ACR Convergence 2021
Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions
Titilayo Ologhobo¹, Bertilia Trieu², Claudia Zurlini¹, Bonnie McGrath¹, Linda Roberts¹, Vilma Briones¹, Pamela Sanchez-Villagomez², Robyn Wiesel¹, Sandra Goldsmith¹ and Laura Robbins¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital of Special Surgery, New York
Background/Purpose: According to the 2020 American Health Ranking System, 26% of adults are physically inactive with a higher prevalence found in adults ages ≥65 years.…
Abstract Number: 0450 • ACR Convergence 2021
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
Mark Hwang¹, Minjae Lee², Lianne Gensler³, Matthew Brown⁴, Amirali Tahanan⁵, Mohammad Rahbar⁶, Theresa Hunter⁷, Mingyan Shan⁸, Mariko Ishimori⁹, John Reveille¹⁰, Michael Weisman¹¹ and Thomas Learch¹², ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²UT Southwestern, Dallas, TX, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴King's College London, London, United Kingdom, ⁵McGovern Medical School, Houston, TX, ⁶Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁷Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Cedars-Sinai Health System, Los Angeles, CA, ¹⁰Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ¹¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹²Cedars-Sinai, Los Angeles, CA
Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…
Abstract Number: 0757 • ACR Convergence 2021
Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study
Paul Studenic¹, Aliaksandra Baranskaya², Stanley Cohen³, Nancy Shadick⁴, Christine Iannaccone⁵, Maria Dahl Mjaavatten⁶, Elisabeth Lie⁷, Tore Kvien⁸, Josef Smolen⁹, Daniel Aletaha¹⁰ and Helga Radner⁹, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women’s Hospital, Topsfield, MA, ⁶Diakonhjemmet Hospital, Haslum, Norway, ⁷Diakonhjemmet Hospital, Oslo, Nepal, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Medical University Vienna, Vienna, Austria
Background/Purpose: The patient global assessment (PGA), typically assessed as 'Considering all of the ways your arthritis has affected you, how do you feel your arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].